Bausch + Lomb Corporation shares T.BLCO are trading up $0.79 at $18.37.

Exclusive real-world insights on more than 9 million de-identified cataract surgery patients aims to advance clinical research, treatment optimization, and patient outcomesSAN FRANCISCO, April 24, ...

Bausch + Lomb addresses recent IOL recall, ensuring safety with enhanced protocols and returning enVista lenses to market ...

Bausch + Lomb announced today that it intends to bring its recently recalled enVista intraocular lenses (IOLs) back to the ...

Bausch + Lomb will return its enVista intraocular lenses to market following a voluntary recall in March after discovering they had certain production and material issues.

"Laser refractive surgery is not a one-size-fits-all solution. When a thorough eye evaluation is done to determine the right procedure for each individual, it offers excellent results with high ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its ...

When cataract eye surgery is performed, the cloudy natural lens of the eye is removed, and a new intraocular lens, or IOL, is implanted to focus light properly and correct vision. The good news is ...

Multiple pharmaceutical agents in clinical trials promise to offer patients eye drops for the management of presbyopia.

In collaboration with the company BRAVE Analytics, researchers at TU Graz have developed a method to detect nanoplastics in ...

New ISO standards categorize SVIOLs into multifocal, EDOF, and FVR IOLs, requiring rigorous clinical testing for ...

ZEISS Medical Technology continued to push the boundaries of surgical precision and workflow efficiency with the introduction ...